PD-1/PD-L1小分子抑制剂的专利研究进展综述

The research progress of the patent for PD-1/PD-L1 small molecular inhibitor

肿瘤免疫疗法是肿瘤治疗领域的新突破,其中,免疫检查点抑制剂在当今肿瘤免疫疗法中备受瞩目。目前已有抗体类药物上市,可治疗多种类型癌症且疗效显著,与之相关的小分子类抑制剂也成为研发热点。本文就近年来公开的PD-1/PD-L1信号通路的小分子抑制剂专利的最新进展进行综述。

Tumor immunotherapy is a new breakthrough in the field of cancer treatment, in which the immunological checkpoint inhibitor PD-1/PD-L1 has attracted much attention in today’s tumor immunotherapy. Currently, several anti-PD-1 and anti-PD-L1 antibodies have been launched, which can treat many types of tumors with remarkable clinical curative effect, and the related small molecule inhibiters have been becoming research hotspots. The progress in patents published in recent years for small molecule inhibitors which can inhibit the PD-1/PD-L1 signaling pathway is reviewed.